Article Details

LBL-047: A Dual-Targeting Breakthrough in Autoimmune Disease Therapy and Its Market ...

Retrieved on: 2025-09-22 06:59:20

Tags for this article:

Click the tags to see associated articles and topics

LBL-047: A Dual-Targeting Breakthrough in Autoimmune Disease Therapy and Its Market .... View article details on hiswai:

Excerpt

These firms rely on blockbuster biologics like Humira and monoclonal antibodies to treat conditions such as rheumatoid arthritis and psoriasis.

Article found on: www.ainvest.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo